IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
(NASDAQ:IDYA) SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract wit...
How does the median overall survival data for this regimen compare to existing treatments for metastatic uveal melanoma and to other pipeline candidates from competitors?
When is IDEAYA planning to submit additional data or seek regulatory approval for the combination therapy, and what milestones could drive the stock in the next 12 months?
What are the expected efficacy and safety results from the darovasertib + crizotinib Phase 2 trial and how will they affect market perception of IDEAYA Biosciences?
about 16 hours ago